Methods	Multicentre, randomised, double-blind, placebo-controlled, parallel-group, no enrichment, LOCF 4-week titration to maximum tolerated dose, or 3600 mg then stable dose for 4 weeks (8 weeks in total)
Participants	Postherpetic neuralgia. N = 229, median age 73 years, 48% women. Pain > 3 months after healing of rash, PI at randomisation > 40/100, initial average daily pain 6.4/10
Interventions	Gabapentin 3600 mg daily (max), n = 113. (83% had > 2400 mg daily) Placebo, n = 116
Outcomes	PGIC moderate or much improved PGIC CTR moderate and much improved No change in pain SF36 and QoL Adverse events Withdrawals
Notes	Oxford Quality Score: R = 1, DB = 2, W = 1, Total = 3 Parke-Davies sponsored
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Yes	“subject-specific bottles based on randomisation schedule”
Blinding? All outcomes	Yes	“identically appearing capsules”
Incomplete outcome data addressed? Efficacy	Unclear	LOCF
Size Efficacy	Yes	229 randomised
Study duration Efficacy	Yes	8-week period
Outcomes reported	Yes	PGIC much improved (top level)